Cellenkos’ Treg therapies aim to treat a range of inflammatory and autoimmune conditions, with CK0804 showing promise in myelofibrosis. The company’s CK0801 candidate for aplastic anaemia has also ...

In addition to CK0804, Cellenkos' CK0801 candidate for aplastic anemia has shown promising efficacy, including transfusion independence in treated patients. Myelofibrosis is a rare, chronic, and ...